Question · asked by 1 review
Oral hydromorphone vs placebo: Substantial benefit: At least 50% reduction in pain, or PGIC much improved
- Population
- adults with chronic neuropathic pain
- Intervention
- Oral hydromorphone
- Comparison
- placebo
- Outcome
- Substantial benefit: At least 50% reduction in pain, or PGIC much improved
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Oral hydromorphone vs placebo Substantial benefit: ≥ 50% reduction in pain PGIC much improved · adults with chronic neuropathic pain The review found no eligible studies for this question. Hydromorphone for neuropathic pain in adults (2016) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.